In Brief: FDA device tracking/PMS public meeting location
This article was originally published in The Gray Sheet
FDA device tracking/PMS public meeting location: Jan. 15 public meeting to discuss how FDA should implement its new discretionary tracking and post-market surveillance powers authorized by the FDA Modernization Act has been relocated to the University of Maryland's Rockville campus. The meeting originally had been scheduled at FDA's Corporate Building in Rockville. For more information, contact FDA's Casper Uldricks at 301/594-4692...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.